Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)

Cedars-Sinai Medical Center

Status: Suspended

Conditions: PDAC - Pancreatic Ductal Adenocarcinoma

Treatments: Diagnostic Test: 6D-MRI

Study type: Interventional

Funder types: Other

Identifiers

NCT04700488

STUDY00000573

Details and patient eligibility

About

The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).

Full description

The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e. vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT).

Enrollment: 36 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy
• Patients able to undergo at least two sets of MRI sessions

Exclusion criteria

• Patients who have previously been treated for PDAC
• Patients unable to undergo MRI exam w/contrast
• Patients with metastatic pancreatic cancer visualized on index diagnostic imaging
• Patients with certain metallic implants
• Patients experiencing claustrophobia
• Persons with allergy to animal dander or animal-instigated asthma

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

36 participants in 1 patient group

6D-MRI

Experimental group

Description:

Participants will undergo 6D-MRI imaging three times throughout the course of the study: once pre-NAT treatment, once during NAT treatment, and once post-NAT treatment.

Treatment:

Diagnostic Test: 6D-MRI